Company Overview: Catalyst Biosciences

Industry News

7 Apr

Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., April 07, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the pricing of an underwritten public offering of units for gross proceeds of $18 million, prior to deducting underwriting discounts...

Read more

28 Mar

Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program

SOUTH SAN FRANCISCO, Calif., March 28, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug Application (IND) for CB 2679d/ISU304....

Read more

16 Feb

Catalyst Biosciences Announces Promotion of Andrew Hetherington to SVP of Technical Operations

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Andrew Hetherington has been promoted to Senior Vice President of Technical Operations. Mr. Hetherington joined Catalyst in September 2015...

Read more

14 Feb

Catalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, provided an update on its clinical development plans for its next-generation Factor VIIa and Factor IX candidates and reiterated its intention to...

Read more

3 Feb

Catalyst Biosciences to Present at 19th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 19th Annual BIO CEO...

Read more

1 Feb

Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factors VIIa and IX at EAHAD Annual Congress

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced positive preclinical results in well-validated models of hemophilia A and B with marzeptacog alfa (activated), a next-generation Factor VIIa, and...

Read more

19 Dec

Catalyst Biosciences Completes Manufacturing Agreements for its Novel Factor VIIa Product, Marzeptacog alpha (activated)

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced it has secured all rights to the manufacturing process for marzeptacog alfa (activated) (formerly known as CB 813d) from Wyeth...

Read more

14 Nov

Catalyst Biosciences Announces Positive Preclinical Data with Subcutaneous Dosing of Coagulation Factor IX at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced positive results from a preclinical study of CB 2679d/ISU304 in well-validated models of hemophilia B. The study highlighted the attractive...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address